BioCentury

7:00 AM GMT, May 25, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Sales & Marketing

Biovail, Cambridge Laboratories, GlaxoSmithKline sales and marketing update

Biovail will acquire worldwide rights to a portfolio of tetrabenazine products from Cambridge for $200 million up front, plus

Read the full 196 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.